Twist Bioscience and Element Biosciences Introduce Accelerated Sequencing Workflow

New Trinity Freestyle™ Workflow Enhances Genomic Sequencing Efficiency

Twist Bioscience Corporation (NASDAQ:TWST) and Element Biosciences have launched the Trinity Freestyle™ Fast Hybridization workflow, an end-to-end sequencing solution designed to significantly reduce sample processing times. This new offering allows researchers to progress from sample to sequencer in as little as five hours, marking a notable advancement in genetic sequencing efficiency.

Developed for Element Biosciences’ AVITI™ sequencing platforms, the workflow integrates Twist Bioscience’s library preparation kits with Element’s on-flow cell enrichment technology. A key innovation is the elimination of several traditional, time-consuming steps, including binding, washing, amplification, and pooling. The workflow features a rapid one-hour hybridization process, considerably shortening the overall time typically required for hybrid capture methods. The new workflow is compatible with Twist Bioscience’s Enzymatic Fragmentation Kit 2.0, suitable for whole exome sequencing and tumor profiling, and the FlexPrep™ UHT Library Preparation Kit, targeting agricultural biology and population genomics testing.

Under an expanded collaboration agreement, Twist Bioscience has secured exclusive access to Element’s Trinity Freestyle workflow for its comprehensive lineup of library preparation kits developed for the AVITI sequencer.

Accelerated Scientific Discovery and Market Positioning

The introduction of the Trinity Freestyle workflow is poised to accelerate scientific discovery across various industries by enhancing the speed and consistency of genomic research. The substantial reduction in processing time is expected to increase the throughput and accessibility of sequencing technologies, potentially broadening their adoption in both academic and clinical settings.

Emily M. Leproust, CEO and co-founder of Twist Bioscience, emphasized the strategic alignment, stating, "While Twist remains sequencer-agnostic, we're excited to deliver purpose-built solutions for Element's platform that unlock performance and simplicity for its growing user base." Similarly, Molly He, CEO and co-founder of Element Biosciences, highlighted the partnership's goal to "accelerate scientific discovery across industries by delivering innovation, consistency, and exceptional support." This collaboration is anticipated to strengthen Twist Bioscience’s market position within the next-generation sequencing segment.

Financial Context and Analyst Perspectives

Financially, Twist Bioscience maintains a healthy balance sheet. According to InvestingPro data, the company reports a current ratio of 3.9 and has demonstrated strong revenue growth of 23% over the last twelve months. These figures suggest a robust operational performance and liquidity position.

Analyst sentiment regarding Twist Bioscience (NASDAQ:TWST) is mixed but generally acknowledges the company's leadership in the synthetic biology market. JPMorgan has adjusted its price target for Twist Bioscience to $25, maintaining an Underweight rating. TD Cowen reduced its price target to $36 but retained a Buy rating. Evercore ISI similarly lowered its price target to $46 while upholding an Outperform rating, citing the company's strong performance in the next-generation sequencing segment and solid gross margin results. These varied perspectives reflect the dynamic nature of the biotechnology sector and ongoing evaluations of market potential and financial outlooks.

Broader Market Dynamics and Future Outlook

The DNA sequencing market continues to experience significant expansion. Projections indicate the market size could reach $34.23 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 18.91% from $14.40 billion in 2025. This growth is driven by a shift in demand from purely academic discovery towards routine clinical testing in areas such as oncology, rare diseases, and infectious disease surveillance. Factors contributing to this trend include a sustained decrease in cost-per-genome, expanding reimbursement frameworks, and government-funded precision medicine initiatives.

The enhanced efficiency offered by the Trinity Freestyle workflow is positioned to contribute to this market growth by making advanced genomic sequencing more accessible and cost-effective. As the industry progresses, the ability to rapidly process samples and gain exclusive access to streamlined workflows will be critical competitive advantages. Future implications for Twist Bioscience and Element Biosciences include potential gains in market share within the competitive landscape, which includes major players such as Illumina, Thermo Fisher Scientific, and Agilent Technologies. The ongoing evolution of sequencing technologies, coupled with strategic partnerships, will remain key factors to monitor in the burgeoning life sciences sector.